2025 ahead ayondo Franchise coming soon
Happy 
xMas Holidays
xMas Holidays
xMas Holidays
|
EQS-News: Cannovum AG
/ Key word(s): Miscellaneous
Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21), one of the market leaders in the medical cannabis market, welcomes progress on the legalization of cannabis.
Highly regarded media outlets in Germany published important details from the German government's plans to legalize cannabis. According to the information available, cannabis is to be approved as a stimulant and sold through pharmacies and specialty stores.
As the market leader in medical cannabis, Cannovum AG welcomes this development. The path of cannabis legalization is gaining speed. A regulatory framework for the industry is within reach.
Pia Marten, CEO and Co-Founder of Cannovum AG: “We are delighted about the upcoming legalization of cannabis. A future market worth more than 8 billion euros per year is emerging.”
Pia Marten continued, "We as Cannovum are well prepared for the sale of cannabis through pharmacies as well as through licensed specialty stores. Already today we are a market leader in medical cannabis, we will take over a top position in the legal cannabis market in Germany.”
For more information on Cannovum AG and Cannovum Health eG, which bundles Cannovum AG's medical cannabis operations, please visit: https://cannovum.de/investor-relations
Contact: Klaus Madzia, IR & PR, Cannovum AG Phone +49 30 3982 163 62, klaus.madzia@cannovum.com
Cannovum AG is the first publicly listed German fully licensed medical cannabis company. The shares are traded on the stock exchanges in Düsseldorf, Munich, Berlin, Hamburg and gettex. Through its subsidiary Cannovum Health eG, it is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the importation of high-quality cannabinoid precursors, medical-scientific education and nationwide distribution for simplified and equitable access to cannabis-based therapies. For more information, visit www.cannovum.de
19.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Cannovum AG |
| Rheinsberger Str. 76/77 | |
| 10115 Berlin | |
| Germany | |
| Phone: | +49 (0)30 3982 16360 |
| E-mail: | ir@cannovum.com |
| Internet: | www.cannovum.com |
| ISIN: | DE000A2LQU21 |
| WKN: | A2LQU2 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich |
| EQS News ID: | 1467081 |
| End of News | EQS News Service |
|
|
1467081 19.10.2022 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
